Navigation Links
TOX/See multi-Drugscreen Panel 3-test THC/MOR300/AMP1000

ProductsTOX/See multi-Drugscreen Panel 3-test THC/MOR300/AMP1000
Company Bio-Rad Laboratories
Item TOX/See multi-Drugscreen Panel 3-test THC/MOR300/AMP1000
Features 
  • ComprehensiveTests for as many as 9 drugs per cassette
  • EfficientOne-step test protocol
  • FastResults in as few as 3 minutes
Description TOX/See™ is a 1-step, hand-held, point-of-care device for the qualitative detection of drug or drug metabolites in human urine.

The TOX/See device can detect up to nine of the most commonly abused drugs in 3 to 8 minutes and requires only a few drops of urine. Each TOX/See cassette is individually packaged to maximize convenience and ease of use. TOX/See features integrated test controls, easy-to-read results, and an 18-month shelf life at room temperature. The completed test card can be photocopied and archived for health and legal records.

The straightforward test protocol is designed for use by all levels of staff in hospitals, emergency departments, correctional facilities, juvenile facilities, police departments, workplaces, and recovery and rehabilitation programs.

Info Bio-Rad Laboratories
Customer Service: 1-800-2-BIORAD
Web site: http://www.bio-rad.com

Related medicine products :

1. TOX/See Rapid Urine Drug Screen Tests
2. TOX/See multi-Drugscreen Panel 10-test (AMP/BAR/BZO/COC/MDMA/MET/MTD/OPI/PCP/THC)
3. TOX/See multi-Drugscreen Panel 10-test (AMP/BAR/BZO/COC/MET/MTD/OPI/PCP/TCA/THC)
4. TOX/See multi-Drugscreen Panel 9-test (PCP/BAR/AMP1000/COC/MET1000/TCA/MOR300/THC/BZO)
5. TOX/See multi-Drugscreen Panel 10-test (AMP/BAR/BZO/COC/MDMA/MET/MTD/OPI/TCA/THC)
6. TOX/See multi-Drugscreen Panel 8-test (AMP1000/COC/MOR300/THC/BZO/MET1000/MTD/BAR)
7. TOX/See multi-Drugscreen Panel 8-test (THC/COC/AMP1000/PCP/BAR/BZO/MOR2000/MTD)
8. TOX/See multi-Drugscreen Panel 8-test (THC/COC/AMP1000/PCP/BAR/BZO/MOR300/MTD)
9. TOX/See multi-Drugscreen Panel 5-test THC/MOR300/AMP1000/COC/BZO
10. TOX/See multi-Drugscreen Panel 5-test THC/COC/PCP/MOR300/AMP1000
11. TOX/See multi-Drugscreen Panel 5-test THC/COC/MOR300/AMP1000/MET1000
The 1296-041 DELFIA Plate Dispense allows the automatic and precise addition of liquids to all wells or to selected strips of the DELFIA microtitration plate. To minimize background and to avoid foam
Precision 2000 is an affordable, innovative solution for automated 96-/384-well microplate liquid handling. With its ability to perform virtually any routine liquid transfer, Precision 2000 replaces
Multidrop DW is a high-speed automated dispenser for Deep Well plates, 1.1 ml test tubes and 96-well plates. Designed for accuracy and precision, the Multidrop DW dispenses up to eight different reag
...nts and increased throughput, particularly for scr...ated dispenser designed for high-throughput screen...ll plates.This new-generation dispenser offers out...- to 384- well plates and dispense up to 8 differe...
Medicine Products:
(Date:12/3/2008)... MEN WITH EMPHYSEMA AT RISK FOR OSTEOPOROSIS , Ne... pulmonary disease (COPD), which includes emphysem...osteoporosis. Researchers from Japan performed che...e patients with COPD. Using these tests, researche...h percentage of low attenuation area (LAA%), which...
(Date:12/3/2008)...dation Reconfirms Commitment to GAC,s Work Advocat...Developing Countries , , WASHINGTON, Dec. 4...or Children (GAC) announced a $100,000 end-of-year...will support GAC,s efforts on an Emergency Preside...in the new Obama administration, ensure children a...
(Date:12/3/2008)...hn D. England, MD, Professor and Chairman of Neuro...ool of Medicine, is the principal investigator of ...or neuropathy a common degenerative nerve disorde...ds for evaluation and management. The studies, pub...008 online issue of Neurology , resulted in recom...
(Date:12/3/2008)...ERDAM, The Netherlands, and LOS ANGELES, Dec. 3 /P... Kari Boiler as the President of Bugaboo,Americas...o North America for,the past 5 years. "Kari Boile...g leader but a great team player with the vision t...says Arjan Muis, CEO of Bugaboo International. , ...
Breaking Medicine News(10 mins):Health News:Journal CHEST: December highlighted studies 2Health News:Jolie-Pitt Foundation Awards Second Grant to Global Action for Children 2Health News:LSUHSC's England leads development of new testing guidelines for common nerve disorder 2Health News:Kari Boiler Named President of Bugaboo Americas 2
...index (BMI), which is the ratio of height and weig...of patients. A lower BMI is associated with a less...BMI, which is associated with obesity and its alli...ome under scrutiny lately, and other techniques th...
...bad High Court today directed Uttar Pradesh govern...lleges in the state imparting education in Indian ... not to continue with counselling and admission pr...e order was passed by Justice Sunil Ambawani on a ...
...to the British government report it was found that...tted to hospital with severe allergic reactions to...o be the most serious and potentially fatal form o...t about 3,000 people suffer from allergic reaction...
...to a study conducted by the researchers at the Uni...diminishes the man's ability to think clearly.// ...ysed about eight unmarried, childless couples in t... beds and on the next day they were asked to perfo...
Other Medicine News:Health News:A high BMI may not determine obesity, researchers say 2
(Date:12/1/2008)...ewswire/ -- New research has found that the availa...hy (CT) scanner in an emergency room can significa...eive a potentially life-saving treatment. Results ...ter (NSMC)-Salem Hospital in Salem, Mass., will be...ological Society of North America (RSNA). , ,...
(Date:12/1/2008)...-- S*BIO Pte Ltd today announced the initiation of...d orally-active JAK2 inhibitor, in leading medical...iopathic myelofibrosis (CIMF). , , The tri...lity of SB1518 in patients with CIMF and is expect...f the study will assess the safety profile and eva...
(Date:12/1/2008)...est policy , , ROCHESTER, Minn., Dec. 1 /P...nic finds the use of the drug therapy etanercept i...te inflammation of the liver caused by excessive c...e published in the December issue of Gastroentero... VIDEO ALERT: Additional audio and video resourc...
(Date:12/1/2008)...stCall/ -- GeoVax Labs, Inc.,(OTC Bulletin Board:...eloping,human vaccines for diseases caused by HIV...tious agents, announced today that the launch of i...in twelve sites across North and South America.,T...e National Institutes of,Health (NIH), and the HI...
Breaking Medicine Technology:Portable CT Increases Chance of Stroke Survival and Recovery 2Portable CT Increases Chance of Stroke Survival and Recovery 3S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Reducing Cost of Health Care by Addressing Workers Compensation Costs 14941 1Reducing Cost of Health Care by Addressing Workers Compensation Costs 14941 2CMPMedica Expands SearchMedica com with Multiple Additional Vertical Search Applications co developed with Convera 28R 29 4144 1CMPMedica Expands SearchMedica com with Multiple Additional Vertical Search Applications co developed with Convera 28R 29 4144 2CMPMedica Expands SearchMedica com with Multiple Additional Vertical Search Applications co developed with Convera 28R 29 4144 3Patient Reported Outcomes 28PROs 29 Improve Cancer Treatment Experts Agree 4142 1Patient Reported Outcomes 28PROs 29 Improve Cancer Treatment Experts Agree 4142 2Patient Reported Outcomes 28PROs 29 Improve Cancer Treatment Experts Agree 4142 3Ardea Biosciences Reports Progress of Clinical Development Programs 3B Provides 2008 Outlook 3B Announces 2007 Financial Results and Provides 2008 Fin 14938 1Ardea Biosciences Reports Progress of Clinical Development Programs 3B Provides 2008 Outlook 3B Announces 2007 Financial Results and Provides 2008 Fin 14938 2Ardea Biosciences Reports Progress of Clinical Development Programs 3B Provides 2008 Outlook 3B Announces 2007 Financial Results and Provides 2008 Fin 14938 3Ardea Biosciences Reports Progress of Clinical Development Programs 3B Provides 2008 Outlook 3B Announces 2007 Financial Results and Provides 2008 Fin 14938 4Ardea Biosciences Reports Progress of Clinical Development Programs 3B Provides 2008 Outlook 3B Announces 2007 Financial Results and Provides 2008 Fin 14938 5Ardea Biosciences Reports Progress of Clinical Development Programs 3B Provides 2008 Outlook 3B Announces 2007 Financial Results and Provides 2008 Fin 14938 6
...vement in Psoriasis,Signs and Symptoms at Week 12;...ieved 90 Percent Improvement, ABBOTT PARK, Ill., M... study results show Abbott,s investigational treat...antly in the majority,of patients treated. At 12 w...ere psoriasis achieved 75 percent improvement in,p...
...ceuticals plc,(LSE: CEN), the Cambridge based biop... independent study in the respected scientific,jou...NS 5161. CeNeS,is developing CNS 5161 as a potenti... study builds on the work that CeNeS has,already u...n ,Synapse, Dr Anat Biegon and her group,at the B...
Other Medicine Technology:Abbott's Investigational Treatment ABT-874 Shows Positive Results,in Phase II Psoriasis Study 2Abbott's Investigational Treatment ABT-874 Shows Positive Results,in Phase II Psoriasis Study 3Abbott's Investigational Treatment ABT-874 Shows Positive Results,in Phase II Psoriasis Study 4Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 2Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 3